RxDoctor Payments DataLook up a doctor →

Lawrence Kemp, MD

Neurology · Lewes, DENPI 1619916855

Payments from drug & device makers

$23,684in general payments, 2019–2025

Across 1,360 payments — averaging $17.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$4K
  • Biogen$2K
  • AbbVie$2K
  • UCB, Inc.$2K
  • Lilly USA, LLC$1K
  • EMD Serono, Inc.$1000
  • plus $13K from 50 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Teva Pharmaceuticals USA, Inc.170$3,566
Biogen96$1,685
AbbVie(2 entities)115$1,624
UCB, Inc.71$1,532
Lilly USA, LLC75$1,035
EMD Serono, Inc.45$1,000
Amgen(2 entities)50$971
Mallinckrodt Hospital Products Inc.26$820
Novartis53$817
Genentech USA, Inc.42$810
Amneal Pharmaceuticals LLC49$792
Eisai Inc.46$773
Acadia Pharmaceuticals Inc42$715
Neurocrine Biosciences, Inc.35$666
Lundbeck LLC34$568
Biohaven Pharmaceutical Holding Company Ltd.56$460
Sunovion Pharmaceuticals Inc.28$420
Kyowa Kirin, Inc.21$398
Pfizer39$395
Neurelis, Inc.19$383
AstraZeneca21$380
Greenwich Biosciences, Inc.18$342
Sanofi19$336
Livanova USA, Inc.17$304
Argenx US, Inc.12$296
Mallinckrodt Enterprises LLC10$250
Supernus Pharmaceuticals, Inc.18$232
Biohaven Pharmaceuticals, Inc.29$228
Otsuka America Pharmaceutical, Inc.10$192
Adamas Pharmaceuticals, Inc.10$154
Sumitomo Pharma America, Inc.9$153
Catalyst Pharmaceuticals, Inc.7$152
Bristol Myers Squibb8$145
Grifols USA, LLC8$144
Jazz Pharmaceuticals Inc.6$137
Acorda Therapeutics, Inc6$92
Alnylam Pharmaceuticals Inc.5$87
Avanir Pharmaceuticals, Inc.5$81
Johnson & Johnson4$75
Upsher-smith Laboratories LLC4$67
Azurity Pharmaceuticals, Inc.3$54
Inspire Medical Systems, Inc.1$42
Xeris Pharmaceuticals, Inc.2$42
Insightec,inc2$38
Medtronic1$32
Avion Pharmaceuticals2$29
Impel Pharmaceuticals Inc.2$26
Tanabe Pharma America, Inc.1$24
Abbott1$19
Merz Pharmaceuticals, LLC1$18
CSL Behring1$15
GE HealthCare1$14
Sanofi-aventis U.S. LLC1$13
E.r. Squibb & Sons, L.L.C.1$13
Arbor Pharmaceuticals, Inc.1$13
Strongbridge US Inc.1$11

How this compares

$23,684 in reported general payments places this provider in the 90th percentile of 61 neurology providers in Delaware.

See all neurology providers in Delaware

Medicare billing

Part B allowed, 2024
$135,283
Medicare patients
644
Services billed
1,376

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Lewes

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →